Coronary heart disease in women: Hormone replacement therapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
For both primary and secondary prevention of coronary heart disease (CHD), it is prudent to use strategies that are of proven benefit and that do not harm patients. In all women, these strategies include lifestyle approaches such as smoking avoidance, proper nutrition, and regular exercise. Lipid-lowering and blood pressure control with pharmacotherapy are indicated in women who do not meet target lipid or blood pressure levels with lifestyle interventions. For women with CHD, aspirin, beta-blockers, and angiotensin-converting enzyme inhibitors should be considered. Widespread under-use of established preventive therapies has been documented in women. These interventions should be emphasized in clinical practice.
For secondary prevention of CHD in women, the American Heart Association (AHA) recommends against initiating hormone replacement therapy (HRT) based on studies that have shown no benefit and early harm. For patients with CHD already on HRT, the decision to continue or stop HRT should be based on established noncoronary benefits and risks and patient preference.
There are insufficient data to suggest that HRT should be initiated for the sole purpose of primary prevention of CHD.
Because the new AHA guidelines recommend placing significant weight on the noncardiac benefits and risks of HRT, it is important to become familiar with these noncardiac effects. It is also important to understand the evidence supporting the AHA’s decision to recommend placing relatively less weight on the cardiac effects of HRT.
- Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613. This randomized controlled trial (HERS) of Prempro vs placebo is the largest published secondary prevention trial of HRT in women with CHD. The results showed no benefit of HRT in cardiac morbidity or mortality after 4 to 5 years. CrossRef
- Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995, 273:199–208.
- Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801–1811. CrossRef
- Jick H, Derby LE, Myers MW, et al.: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348:981–983. CrossRef
- Daly E, Vessy MP, Hawkins MM, et al.: Risk of venous thromboembolism in user of hormone replacement therapy. Lancet 1996, 348:977–980. CrossRef
- Grady D, Wenger N, Herrington D, et al.: Postmenopausal hormone therapy increases risk of venous thromboembolic disease—the Heart and Estrogen/ progestin Replacement Study. Ann Intern Med 2000, 132:689–696.
- The Coronary Drug Project design and methods, and baseline results. Coronary Drug Project Research Group. Circulation 1973, 47(suppl 3):1–60.
- Stampfer MJ, Willett WC, Colditz GA, et al.: A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985, 313:1044–1049. CrossRef
- Wilson PW, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular mortality in women over 50. The Framingham Study. N Engl J Med 1985, 313:1038–1043. CrossRef
- Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016–1037.
- Sullivan JM, Vander Zwaag R, Lemp GF, et al.: Postmenopausal estrogen use and coronary athersclerosis. Ann Int Med 1988, 108:358–363.
- Matthews KA, Kuller LH, Wing RR, et al.: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996, 143:971–978.
- Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522–529. This randomized controlled trial (ERA) found no angiographic differences in 309 women randomized to Premarin, Prempro, or placebo. CrossRef
- Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study. Ann Intern Med 2001, 135:1–8.
- Heckbert SR, Kaplan RC, Weiss NS, et al.: Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001, 161:1709–1713. CrossRef
- Psaty B, Smith NL, Lemaitre RN, et al.: Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001, 285:906–913. CrossRef
- National Institutes of Health, National Heart, Lung, and Blood Institute. Women’s Health Initiative. URL: www.nhlbi.nih.gov/whi/hrt-en.htm; accessed December 14, 2001.
- Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 104:499–503. This article includes the American Heart Association’s November 2001 guidelines regarding HRT and cardiovascular disease in women and the evidence supporting these guidelines.
- The Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997, 350:1047–1059. CrossRef
- Scgairer C, Lubin J, Troisi R, et al.: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000, 283:485–491. CrossRef
- Ross R, Paganini-Hill A, Wan P, Pike M: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000, 92:328–332. CrossRef
- Simon JA, Hsia J, Cualey JA, et al.: Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001, 103:638–642.
- Viscoli CM, Brass LM, Kernan WN, et al.: Estrogen after ischemic stroke: effect of estrogen replacement on risk of recurrent stroke and death in the Women’s Estrogen for Stroke Trial (WEST) [abstract]. Stroke 2001, 32:329.
- Cushing KL, Weiss NL, Voigt LF, et al.: Risk of endometrial cancer in relation to use of low-dose unopposed estrogens. Obstet Gynecol 1998, 91:35–39. CrossRef
- Grodstein F, Martinez E, Platz EA, et al.: Postmenopausal hormone use and risk of colorectal cancer and adenoma. Ann Intern Med 1998, 128:705–712.
- Yaffe K, Sawaya G, Lieberburg I, Grady D, et al.: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998, 279:688–695. CrossRef
- Mulnard R, Cotman C, Kawas C, et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000, 283:1007–1015. CrossRef
- Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA 2001, 285:2909–2910. CrossRef
- Greendale G, Reboussin B, Hogan P, et al.: Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998, 92:982–988. CrossRef
- Stampfer MJ, Hu FB, Manson JE: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000, 343:16–22. CrossRef
- Coronary heart disease in women: Hormone replacement therapy
Current Treatment Options in Cardiovascular Medicine
Volume 4, Issue 2 , pp 129-136
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links